Prosecution Insights
Last updated: April 19, 2026
Application No. 18/275,055

FLAVOUR COMPOSITIONS

Final Rejection §DP
Filed
Jul 31, 2023
Examiner
ROBERTS, LEZAH
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Givaudan SA
OA Round
2 (Final)
48%
Grant Probability
Moderate
3-4
OA Rounds
4y 4m
To Grant
85%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allow Rate
363 granted / 750 resolved
-11.6% vs TC avg
Strong +36% interview lift
Without
With
+36.4%
Interview Lift
resolved cases with interview
Typical timeline
4y 4m
Avg Prosecution
78 currently pending
Career history
828
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
49.2%
+9.2% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
16.0%
-24.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 750 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed October 22, 2025, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims Obvious-Type Double Patenting 1) Claims 1 and 3-7 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 and 18-19 of copending Application No. 17/769,198 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims are coextensive insofar as both sets of claims recites compounds of formula I. The instant claims differ from the copending claims insofar as the instant claims recite a composition whereas the copending claims recite a method of using formula I. However it would have been obvious to one of ordinary skill in the art to have used the composition of the instant claims in the method of the copending claims because they comprise the same active agent, compounds of formula 1. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Arguments The Examiner submits that the copending claims do not appear to recite amounts and therefore would encompass any amount. Therefore the amount is encompassed by the copending claims. In regards to the mint, both sets of claims use open language and copending claims do not exclude a mint flavor. Therefore the instant claims are obvious over the copending claims. 2) Claims 1 and 3-7 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-7 and 9-16 of copending Application No. 18/276,412 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims are coextensive insofar as both sets of claims recites compounds of formula I. The instant claims differ from the copending claims insofar as the instant claims recite a composition and the compound of formula I are species of the compounds of the copending claims. Further, the copending claims recite a method of using formula I and a composition. However it would have been obvious to one of ordinary skill in the art to have used the composition of the instant claims in the method of the copending claims because they comprise active agents encompassed by the formula of the copending claims. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Arguments The Examiner submits that the copending claims do not appear to recite amounts and therefore would encompass any amount. Therefore the amount is encompassed by the copending claims. In regards to the mint, both sets of claims use open language and the copending claims do not exclude a mint flavor. Therefore the instant claims are obvious over the copending claims. 3) Claims 1 and 3-7 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-17 of copending Application No. 18/005,404 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims are coextensive insofar as both sets of claims recites compounds of formula I. The instant claims differ from the copending claims insofar as the compositions of the instant claims comprise an additional flavor agent whereas the copending claims recite a solvent. Menthol is also a cooling compound. "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose. See MPEP 2144.06. Therefore it would have been obvious to one of ordinary skill in the art to have added menthol to the composition of the copending claims because it is also a cooling agent. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Arguments The Examiner submits that the copending claims do not appear to recite amounts and therefore would encompass any amount. Therefore the amount is encompassed by the copending claims. In regards to the mint, both sets of claims use open language and the copending claims do not exclude a mint flavor. Therefore the instant claims are obvious over the copending claims. 4) Claims 1 and 3-7 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-2 and 19 of copending Application No. 18/005,425 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims are coextensive insofar as both sets of claims recites compounds of formula I. The instant claims differ from the copending claims insofar as the compositions of the instant claims comprise an additional flavor agent whereas the copending claims recite a solvent. Menthol is also a cooling compound. "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose. See MPEP 2144.06. Therefore it would have been obvious to one of ordinary skill in the art to have added menthol to the composition of the copending claims because it is also a cooling agent. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Arguments The Examiner submits that the copending claims do not appear to recite amounts and therefore would encompass any amount. Therefore the amount is encompassed by the copending claims. In regards to the mint, both sets of claims use open language and the copending claims do not exclude a mint flavor. Therefore the instant claims are obvious over the copending claims. Conclusion Claims 1 and 3-7 are rejected. No claims allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LEZAH ROBERTS whose telephone number is (571)272-1071. The examiner can normally be reached Monday-Friday 11:00-7:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached at 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LEZAH ROBERTS/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Jul 31, 2023
Application Filed
Aug 09, 2025
Non-Final Rejection — §DP
Oct 22, 2025
Response Filed
Feb 08, 2026
Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594229
Personal Care Compositions and Methods for the Same
2y 5m to grant Granted Apr 07, 2026
Patent 12594241
TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12582583
ORAL CARE PRODUCT COMPRISING AN ORAL CARE RHEOLOGICAL SOLID COMPOSITION
2y 5m to grant Granted Mar 24, 2026
Patent 12558387
MULTI-VIRUS ANTI-INFECTIVITY AND PRO-IMMUNITY ASSEMBLY
2y 5m to grant Granted Feb 24, 2026
Patent 12551417
STABILIZED STANNOUS COMPOSITIONS
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
48%
Grant Probability
85%
With Interview (+36.4%)
4y 4m
Median Time to Grant
Moderate
PTA Risk
Based on 750 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month